Company / Financials
Foghorn Therapeutics Inc. Financials
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$22.6M
FY2025 · -33.8% YoY
Net Income
-$86.6M
FY2025 · +12.0% YoY
Profit Margin
-383.2%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$198.1M
FY2025
Total Debt
-
FY2025
Equity
-$45.5M
FY2025
ROA
-43.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$22.6M-33.8% YoYNet Income HistoryProfit after all expenses and taxes-$86.6M+12.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$102.7M+4.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$28.4M-12.4% YoYR&D Expense HistoryResearch and development spending$94.5M-13.8% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0-100.0% YoYEPS (Basic) HistoryBasic earnings per share-$1.58+32.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.58+32.5% YoYShares Outstanding HistoryWeighted average diluted shares outstanding55.6M+31.5% YoY